Brief: Lipocine Inc - Announces Favorable Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depression (PPD)

Lipocine

15/09/2022 11:50

Sept 15 (Reuters) - Lipocine Inc  LPCN.O :
    * LIPOCINE INC - ANNOUNCES FAVORABLE REGULATORY PATHWAY ON
ORAL
LPCN 1154 FOR POST-PARTUM DEPRESSION (PPD)
    * LIPOCINE INC - FDA AGREES WITH LIPOCINE ESTABLISHING LPCN
1154
PATHWAY TO EFFICACY THROUGH PHARMACOKINETIC BRIDGE TO APPROVED
IV INFUSION BREXANOLONE
    * LIPOCINE INC - HAS DEMONSTRATED THAT THE BREXANOLONE
EXPOSURE OF
LPCN 1154 IS SIMILAR TO THE LEVELS OBSERVED IN THIRD TRIMESTER
PREGNANT WOMEN SAMPLES
    * LIPOCINE INC - PILOT PK BRIDGE STUDY IS PLANNED WITH
RESULTS
EXPECTED IN 1Q 2023
    * LIPOCINE INC - PLANS ADDITIONAL WORK IN PARALLEL TO PURSUE
A
WELL DIFFERENTIATED LABEL


Further company coverage:  LPCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))